Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
10x Genomics (NasdaqGS:TXG) announced a multi year research collaboration with Lausanne University Hospital focused on cancer diagnostics using single cell and spatial technologies.
The partnership aims to generate clinically actionable biomarkers and integrate them directly into cancer care workflows.
The collaboration will use large scale patient data to explore more personalized treatment options in oncology.
10x Genomics enters this collaboration with Lausanne University Hospital as a company already closely watched by growth focused healthcare investors. The stock trades at $47.27 and is up 21.0% over the past 30 days and 184.4% year to date. Over the past year, NasdaqGS:TXG has gained 261.4%, although returns over the past 3 and 5 years show periods of sizable drawdowns.
This new partnership adds a clinically oriented project to 10x Genomics’ existing research footprint and may influence how investors view its role in cancer care. The focus on biomarker discovery and potential integration into treatment protocols gives shareholders a concrete development to monitor as data and clinical readouts emerge over the coming years.
Stay updated on the most important news stories for 10x Genomics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on 10x Genomics.
NasdaqGS:TXG Earnings & Revenue Growth as at Aug 2026
Quick Assessment
⚖️ Price vs Analyst Target: 10x Genomics trades at $47.27, which is close to the one standard deviation upper band of the $41.54 analyst target range and near the $50 high target.
✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading 44.2% below the current internal fair value estimate.
✅ Recent Momentum: The 30 day return of 21.0% shows strong short term momentum into the collaboration announcement.
There’s only one way to know the right time to buy, sell or hold 10x Genomics. Head to Simply Wall St’s company report for the latest analysis of 10x Genomics’s Fair Value.
Key Considerations
📊 This Lausanne University Hospital collaboration ties 10x Genomics’ single cell and spatial tools directly to cancer diagnostics, which could become a core part of many investors’ thesis.
📊 Watch for biomarker outputs, incorporation into hospital workflows, and any impact on revenue from instruments and consumables linked to oncology use cases.
⚠️ The company remains loss making and is not forecast to reach profitability in the next 3 years, while recent insider selling may concern some shareholders.
Dig Deeper
For the full picture including more risks and rewards, check out the complete 10x Genomics analysis. Alternatively, you can check out the community page for 10x Genomics to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TXG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com